ONC · BeOne Medicines Ltd. · Stock research

Current Thesis

The binary that gated this name resolved on 2026-08-05, and it resolved up: Q2 revenue $1.705B against $1.591B consensus, non-GAAP diluted EPS per ADS $3.84 against $1.44, and a full-year 2026 revenue guide lifted to $6.6–6.8B from $6.3–6.5B. The fundamental leg an investor is buying is intact — US BRUKINSA volume compounding at 31% YoY on the highest sustained new-patient starts since launch, with gross margin at 90% and GAAP operating income at $325M versus $88M a year earlier. What has changed is the flow. The July repricing wave (Jefferies upgrade to Buy, JPM $425, RBC $451) was a re-rate; the 2026-08-06 wave was arithmetic — Truist $416→$418, Citizens $396→$405, RBC $451→$450 lower — and the stock did not take out its high on a beat-and-raise. The 2026-08-14 close of $347.48 sits 7.9% below the split/dividend-adjusted 52-week high of $377.47. The narrative is maturing — well known, still working, moderating flow, with no dated company event inside 30 days to force the next leg.

Bullish and bearish views on BeOne Medicines Ltd.

The model's bull view on BeOne Medicines Ltd. (ONC), in brief: Q2 2026 (2026-08-05): total revenue $1.705B vs $1.591B consensus, +30% YoY; non-GAAP diluted EPS/ADS $3.84 vs $1.44 consensus; GAAP diluted EPS/ADS $2.05, +144% YoY. The bear view: A beat-and-raise of that size did not produce a new high. Both cases follow in full.

Bull Case

• Q2 2026 (2026-08-05): total revenue $1.705B vs $1.591B consensus, +30% YoY; non-GAAP diluted EPS/ADS $3.84 vs $1.44 consensus; GAAP diluted EPS/ADS $2.05, +144% YoY.
• BRUKINSA global Q2 revenue $1.25B, +31% YoY; US sales $893M, +31%, attributed by the company to the highest level of sustained new-patient starts since launch. The US deceleration flagged as the fundamental crack ahead of the print did not appear.
• FY2026 guidance raised for the second consecutive quarter: $6.3–6.5B (2026-05-06) → $6.6–6.8B (2026-08-05), against a $6.479B consensus. GAAP operating income guided $1.0–1.1B, non-GAAP $1.7–1.8B.
• Operating leverage is showing in cash, not just non-GAAP: Q2 gross margin 90% vs 87% YoY, operating cash flow $463M vs $264M, free cash flow $435M vs $220M.
• Second commercial product landed 2026-05-13: FDA accelerated approval of BEQALZI (sonrotoclax) in relapsed/refractory mantle-cell lymphoma after ≥2 prior lines including a BTK inhibitor — ORR 52%, median duration of response 15.8 months across 103 patients in BGB-11417-201. First BCL-2 inhibitor approved in MCL.
• 2026-08-10 Revolution Medicines agreement: exclusive development and commercialization rights to four clinical-stage RAS(ON) inhibitors (daraxonrasib, elironrasib, zoldonrasib, RMC-5127) across selected Asian markets excluding Japan and South Korea, plus combination studies pairing BeOne's PRMT5 inhibitor BGB-58067 and trispecific BG-T187 with daraxonrasib or zoldonrasib. Extends the story past heme into RAS-addicted solid tumours.
• Non-BRUKINSA lines are growing: TEVIMBRA $229M (+18% YoY), Europe revenue $208M (+37%), in-licensed/other $204M (+28%) in Q2.

Bear Case

• A beat-and-raise of that size did not produce a new high. Nine trading days later the 2026-08-14 close of $347.48 was still 7.9% under the $377.47 adjusted-series 52-week high. When the best available news does not clear the prior peak, the marginal buyer is already accounted for.
• The 2026-08-06 price-target cluster was incremental — TD Cowen $454, RBC $450 (cut from $451), Guggenheim $430, Truist $418 (from $416), Citizens $405 (from $396). Sell-side is nudging targets to keep pace with price rather than re-rating the franchise.
• Frontline CLL, the largest prize for the BRUKINSA + sonrotoclax combination, has a crack: trade coverage (oncologypipeline.com / ApexOnco) reports CELESTIAL-301 did not demonstrate statistical superiority on the uMRD endpoint versus venetoclax + obinutuzumab, with the independent data-monitoring committee recommending continuation to the PFS primary endpoint. The announcement date was not confirmed in the sources retrieved here; the PFS readout is the resolving event.
• The Revolution Medicines structure has BeOne funding and running a global registrational Phase 3 for a partner asset. That is real spend against the $1.7–1.8B non-GAAP operating income guide; economics of the deal were not disclosed in the summaries retrieved.
• Calquence (AstraZeneca) remains the other share-taker into the Imbruvica cliff. The Q2 print showed BRUKINSA winning, not the war being over.
• A CNY446M (~$62M) China tax settlement disclosed 2026-06-26 was flagged as a Q2 GAAP item; the retrieved Q2 summaries do not break out its line, so its drag on the $2.05 GAAP figure is not separately verifiable from here.

Setup & Price Structure

• Reference close 2026-08-14: $347.48. RSI(14) 63.7 — momentum without an overbought extension. Three-month return +18.5%. Distance from the adjusted-series 52-week high $377.47: −7.9%.
• The pre-print consolidation shelf sat near $326 (2026-07-24 close $325.90). The post-print advance has held above that shelf, which makes it the structural reference for the whole August leg.
• The 2026-08-06 target band runs $405–454, entirely above the 2026-08-14 close. Every covering analyst in the recent feed is positioned constructive; there is no contrarian cushion if a franchise number disappoints.
• Crowding observables, stated as observables: eleven price-target actions clustered between 2026-07-01 and 2026-08-06; no earnings date inside the next 30 days; low index beta (0.49 per prior coverage) so this grinds rather than gaps; RSI in the low 60s rather than the 80s. The filing feed for this window returned no Form 4 activity — that is absence of data, not evidence that no insider sold.
• The gap between the last close and $377.47 is the measurable objective. A reclaim of that level on expanding volume would date a re-acceleration; failure to reclaim it while new targets keep printing is what a saturating narrative looks like.

Catalyst Calendar (next 30 days)

• ~2026-08-31 (est.): half-year interim report with US-GAAP-to-IFRS reconciliation, a non-US listing / Swiss-domicile requirement. Low incremental information after the 2026-08-05 US-GAAP release; only matters if reconciled figures or segment detail diverge.
• By 2026-12-31 (company target): Phase 3 starts for the GPC3 x 4-1BB bispecific and the B7-H4 ADC.
• Q3 2026 results: early November, date not yet announced — outside the 30-day window. The calendar between now and then is genuinely thin, which is itself the near-term condition.

Elapsed catalysts

• H2 2026, no date published (from the 2026-08-05 Q2 milestone slides): tacabrutideg Phase 2 data in relapsed/refractory CLL with a potential accelerated-approval submission; MANGROVE interim analysis and submission readiness in frontline MCL; TEVIMBRA Phase 3 data in first-line HER2+ gastroesophageal adenocarcinoma. Any could land inside the window unannounced; none carries a published date. (passed 21d ago)

What Would Change Our Mind

The structure that matters is the late-July shelf near $326 that the August advance was built on; losing it means the post-print re-rate was fully retraced by sellers who had the beat in hand. In price terms, a weekly close below $315 breaks that leg. On fundamentals, the number to watch is BRUKINSA US growth: +31% YoY in Q2 is what the multiple is paying for, and a Q3 print below the mid-20s% would flip the franchise story from share capture to maturation. A guide merely reaffirmed at $6.6–6.8B — after February's $6.2–6.4B, May's $6.3–6.5B and August's raise — ends the ratchet that has driven the target band higher. On the pipeline, a CELESTIAL-301 PFS readout without superiority would cap sonrotoclax near its R/R MCL label and remove the frontline-CLL leg entirely. And the theme flips to saturated if the next sell-side wave arrives as $450+ targets with no estimate revisions while price stays under $377.47.

Correlation Notes

• Beta near 0.49 (prior coverage figure) means index direction explains little here; the name trades on franchise data and label news. Drawdowns in high-multiple growth do not automatically transmit.
• Direct read-across pairs: AstraZeneca (Calquence, the competing BTK share-taker), AbbVie and J&J (Imbruvica's 2026 US/EU patent cliff, the share pool being redistributed), AbbVie/Roche (Venclexta, the incumbent sonrotoclax is attacking), and — new since 2026-08-10 — Revolution Medicines, whose shares rose on the announcement of the BeOne-funded Phase 3.
• Policy correlation runs through US-China pharma exposure and drug-tariff headlines. The 2026-07-23 $300M New Jersey R&D/manufacturing expansion, taking total US manufacturing investment past $1B, is the company's explicit hedge against that channel.
• Against XBI, the profitability profile (90% gross margin, $435M free cash flow in Q2) argues this trades closer to large-cap pharma than to the unprofitable-biotech complex; correlation to rate-sensitive biotech beta should be looser than the sector label implies.